Literature DB >> 16091246

The role of viral fitness in HIV pathogenesis.

Jason D Barbour1, Robert M Grant.   

Abstract

The development of clinical symptoms, and clinical progression among persons infected with HIV-1 is the manifestation of the effects of the pathogenic viral life cycle of HIV-1. Individual variants of HIV-1 vary widely in features that determine viral fitness and virulence. HIV-1 exploits host antiviral responses, the APOBEC3G cytidine deaminase, and the low-fidelity HIV-1 reverse transcriptase, to ensure new variants with novel phenotypic features are continually present for expansion in response to changing conditions in the host, such as immune responses, or antiretroviral therapy. This high-level variance has led to a wide range in observed fitness and virulence, across strains of HIV-1. The HIV-1 pol replication capacity assay (pol RC) measures features of viral fitness, associates with elevated CD4+ T-cell counts, yet is not strongly associated with HIV-1 RNA levels. The biological basis for elevated CD4+ T-cell counts among those carrying a virus of low pol RC may be because of lowered virus infectivity, or restricted tissue replication.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16091246     DOI: 10.1007/s11904-996-0006-1

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN: 1548-3568            Impact factor:   5.071


  22 in total

1.  Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy.

Authors:  M Nijhuis; R Schuurman; D de Jong; J Erickson; E Gustchina; J Albert; P Schipper; S Gulnik; C A Boucher
Journal:  AIDS       Date:  1999-12-03       Impact factor: 4.177

2.  Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome.

Authors:  Qin Yu; Renate König; Satish Pillai; Kristopher Chiles; Mary Kearney; Sarah Palmer; Douglas Richman; John M Coffin; Nathaniel R Landau
Journal:  Nat Struct Mol Biol       Date:  2004-04-18       Impact factor: 15.369

3.  Selected sexual practices of San Francisco heterosexual men and risk of infection by the human immunodeficiency virus.

Authors:  W Winkelstein; M Samuel; N S Padian; J A Wiley
Journal:  JAMA       Date:  1987-03-20       Impact factor: 56.272

4.  Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection.

Authors:  S G Deeks; J D Barbour; J N Martin; M S Swanson; R M Grant
Journal:  J Infect Dis       Date:  2000-03       Impact factor: 5.226

5.  Impaired replication of protease inhibitor-resistant HIV-1 in human thymus.

Authors:  C A Stoddart; T J Liegler; F Mammano; V D Linquist-Stepps; M S Hayden; S G Deeks; R M Grant; F Clavel; J M McCune
Journal:  Nat Med       Date:  2001-06       Impact factor: 53.440

6.  Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase.

Authors:  L M Mansky; H M Temin
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

7.  Persistence of primary drug resistance among recently HIV-1 infected adults.

Authors:  Jason D Barbour; Frederick M Hecht; Terri Wrin; Teri J Liegler; Clarissa A Ramstead; Michael P Busch; Mark R Segal; Christos J Petropoulos; Robert M Grant
Journal:  AIDS       Date:  2004-08-20       Impact factor: 4.177

8.  Gag non-cleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistant human immunodeficiency virus type 1.

Authors:  Lay Myint; Masakazu Matsuda; Zene Matsuda; Yoshiyuki Yokomaku; Tomoko Chiba; Aiko Okano; Kaneo Yamada; Wataru Sugiura
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

9.  Infection of the SCID-hu mouse by HIV-1.

Authors:  R Namikawa; H Kaneshima; M Lieberman; I L Weissman; J M McCune
Journal:  Science       Date:  1988-12-23       Impact factor: 47.728

10.  Higher CD4+ T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infection.

Authors:  Jason D Barbour; Frederick M Hecht; Terri Wrin; Mark R Segal; Clarissa A Ramstead; Teri J Liegler; Michael P Busch; Christos J Petropoulos; Nicholas S Hellmann; James O Kahn; Robert M Grant
Journal:  J Infect Dis       Date:  2004-06-18       Impact factor: 5.226

View more
  4 in total

1.  High-avidity, high-IFNγ-producing CD8 T-cell responses following immune selection during HIV-1 infection.

Authors:  Niamh M Keane; Steven G Roberts; Coral-Ann M Almeida; Tanya Krishnan; Abha Chopra; Emma Demaine; Rebecca Laird; Monika Tschochner; Jonathan M Carlson; Simon Mallal; David Heckerman; Ian James; Mina John
Journal:  Immunol Cell Biol       Date:  2011-05-17       Impact factor: 5.126

2.  Molecular basis for a lack of correlation between viral fitness and cell killing capacity.

Authors:  Mónica Herrera; Juan García-Arriaza; Nonia Pariente; Cristina Escarmís; Esteban Domingo
Journal:  PLoS Pathog       Date:  2007-04       Impact factor: 6.823

3.  Tenofovir treatment augments anti-viral immunity against drug-resistant SIV challenge in chronically infected rhesus macaques.

Authors:  Karin J Metzner; James M Binley; Agegnehu Gettie; Preston Marx; Douglas F Nixon; Ruth I Connor
Journal:  Retrovirology       Date:  2006-12-21       Impact factor: 4.602

Review 4.  Retrospective on the all-in-one retroviral nucleocapsid protein.

Authors:  Jean-Luc Darlix; Hugues de Rocquigny; Olivier Mauffret; Yves Mély
Journal:  Virus Res       Date:  2014-06-04       Impact factor: 3.303

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.